newsfilter
← Latest News
PR Newswire·

IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors

  • IDEAYA Biosciences nominated IDE101, a potential first-in-class dual CDK inhibitor, as its next development candidate.
  • IDE101 targets CDKN2A-deficiency, a tumor suppressor loss occurring in ~10-15% of all solid tumors & ~70% of pancreatic ductal adenocarcinoma.
  • Preclinical data shows encouraging activity for IDE101 as a monotherapy & in combination with RAS inhibitors or IDEAYA's proprietary PRMT5 inhibitor IDE892 in MTAP-deficient models.
  • IND-enabling studies are currently underway to support an Investigational New Drug filing to the FDA in the first half of 2027.
  • The preclinical profile & combination results for IDE101 will be presented at IDEAYA's London R&D Day.
  • IDE101 was developed using IDEAYA's physics-based ligand design platform & is characterized as a highly potent & selective dual CDK inhibitor.
Company
IDEAYA Biosciences, Inc.
Keywords
IDEAYA Biosciences, Inc.